Search research articles
Contact Us
Filters
Showing results (201-210 of 225) with videos related to
Page
of 23
Sort By:
Surgery
|
June 1, 2025
Minimally invasive surgery could be attempted with preoperatively predictable difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy: A large multicenter study
Hanbo Pan, Hang Chen, Weicheng Kong, et al.
Nature Medicine
|
April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trial
Byoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study Results
Ziming Li, Zhengbo Song, Yanqiu Zhao, et al.
The Lancet. Oncology
|
February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Ziming Li, Yan Wang, Yuping Sun, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Nature
|
October 26, 2022
Measurement of <sup>19</sup>F(p, γ)<sup>20</sup>Ne reaction suggests CNO breakout in first stars
Liyong Zhang, Jianjun He, Richard J deBoer, et al.
Nature Genetics
|
March 21, 2026
A pangenome reference and population studies link structural variants with breeding traits in Gossypium hirsutum
Yan Zhang, Zhengwen Sun, Shilin Tian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
Zhengbo Song, Ziming Li, Yiping Zhang, et al.
Cancer
|
August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
Chunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Thoracic Cancer
|
October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Wenxian Wang, Qian Wang, Chunwei Xu, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 225) with videos related to
Sort By:
Page
of 23
Surgery
|
June 1, 2025
Minimally invasive surgery could be attempted with preoperatively predictable difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy: A large multicenter study
Hanbo Pan, Hang Chen, Weicheng Kong, et al.
Nature Medicine
|
April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trial
Byoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study Results
Ziming Li, Zhengbo Song, Yanqiu Zhao, et al.
The Lancet. Oncology
|
February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Ziming Li, Yan Wang, Yuping Sun, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Nature
|
October 26, 2022
Measurement of <sup>19</sup>F(p, γ)<sup>20</sup>Ne reaction suggests CNO breakout in first stars
Liyong Zhang, Jianjun He, Richard J deBoer, et al.
Nature Genetics
|
March 21, 2026
A pangenome reference and population studies link structural variants with breeding traits in Gossypium hirsutum
Yan Zhang, Zhengwen Sun, Shilin Tian, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
Zhengbo Song, Ziming Li, Yiping Zhang, et al.
Cancer
|
August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
Chunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Thoracic Cancer
|
October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Wenxian Wang, Qian Wang, Chunwei Xu, et al.
Page
of 23